Environmental risk factors are associated with autoimmune hepatitis

Craig Lammert1 | Sai N. Chalasani1 | Elizabeth J. Atkinson2 | Bryan M. McCauley2 | Konstantinos N. Lazaridis2

1Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA
2Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA

Correspondence
Craig Lammert, MD, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 702 Rotary Circle, Suite 205, Indianapolis, IN 46202, USA.
Email: clammert@iu.edu

Funding information
CL is supported by NIDDK K23DK11456.

Handling Editor: Ana Lleo

Abstract

Background: Failure of immunologic homeostasis and resultant hepatocyte destruction in autoimmune hepatitis (AIH) is likely the result of environmental triggers within a permissive genetic architecture.

Aims: We aimed to identify risk factors associated with AIH in a well-phenotyped AIH cohort.

Methods: We prospectively collected environmental questionnaires from 358 AIH cases and 563 healthy controls. Response frequencies were compared using logistic regression, adjusting for age at recruitment, sex and education.

Results: AIH cases were more likely to ever have a urinary tract infection (UTI) (53.6% vs 33.9%, \( P < .001 \)) and recurrent UTI (more than 1 per year) (23.5% vs 15.9%, \( P = .002 \)) compared to controls. Female cases more frequently had ever used oral contraceptives (83.0% vs 73.7%, \( P = .006 \)), fewer pregnancies (median = 1 vs 3, \( P < .001 \)) and less often used hormone replacement therapy compared to controls (28.5% vs 60.1%, \( P < .001 \)). Current smoking was more prevalent in cases (18.9% vs 7.4%, \( P = .022 \)), yet no difference according to historical smoking behaviours was observed. Finally, cases were less likely to have history of mumps (32.4% vs 53.1%, \( P = .011 \)) and rheumatic fever (1.1% vs 4.4%, \( P = .028 \)), but reported higher vaccination frequency to chicken pox (38% vs 28.1%), measles (66.5% vs 39.3%), mumps (58.7% vs 34.6%), rubella (55.3% vs 32.7%), pertussis (59.8% vs 40.1%) and pneumococcus (47.2% vs 39.4%) (\( P < .002 \)).

Conclusions: Environmental factors are important in AIH pathogenesis. Replication of these findings and prospective examination may provide new insight into AIH onset and outcomes.

Keywords
autoimmune hepatitis, environment, infection, oestrogen, UTI, vaccine

Abbreviations: AIH, Autoimmune Hepatitis; GRACE, Genetic Repository of Autoimmune Liver Disease and Contributing Exposures; PBC, Primary Biliary Cholangitis; PSC, Primary Sclerosing Cholangitis; UC, Ulcerative Colitis.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. Liver International published by John Wiley & Sons Ltd.
INTRODUCTION

Broken immune tolerance and failure of immunologic homeostasis underlying autoimmune hepatitis (AIH) pathogenesis are likely the result of environmental triggers in the background of a permissive genetic architecture. Similar to other autoimmune diseases, the Human Leucocyte Antigen (HLA) locus at 6p21 has been associated with AIH in prior candidate gene studies and confirmed by the only genome-wide association study. A single causal variant does not exist, and further complicating the HLA-AIH association is the presence of alleles conferring disease risk and protection. In addition to genetic factors, environmental triggers such as viral infections and drug exposures have been temporally associated with AIH onset.

For other autoimmune diseases, liver diseases, primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), environmental risk assessments have provided a more complete understanding of disease risk, onset and possible modifiable factors. To date, such assessments in AIH are incomplete. Case series and small retrospective studies have linked a variety of drugs, specifically nitrofurantoin and minocycline, and viruses such as Epstein-Barr virus, varicella zoster virus, viral hepatitis A, B and C, to AIH. Unfortunately, these potentially important triggers are seldom considered systematically in clinical practice. Further evidence supports an environmental role in AIH pathogenesis, as factors such as microbiome diversity and psychosocial stress have also been associated with disease.

In this study, we aimed to identify associations between AIH and lifetime environmental exposures as well as lifestyles, personal and family histories using the Genetic Repository of Autoimmune Liver Diseases and Contributing Exposures (GRACE) study.

METHODS

AIH cases and controls

The GRACE study contains consecutively recruited AIH patients (cases) from Indiana University. Details regarding the establishment of this registry have been published previously. The GRACE study was developed in 2014 to collect well-phenotyped AIH cases to pursue investigation into genetic and environmental contribution to disease development. The diagnosis of AIH among cases was based on clinically accepted criteria as per the recent clinical guidelines.

Controls were serially recruited from the Mayo Clinic Division of General Internal Medicine during annual visits for preventive medical examination. Control exclusion criteria included evidence of prior or current liver disease (known alcohol, fatty liver or viral hepatitis (per clinical notes, imaging or serology)) or any historical abnormal liver enzyme levels. All participants in the study had informed consent collected by study staff. This study included cohorts that adhere to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the Institutional Review Board of Indiana University and Mayo Clinic.

Questionnaire establishment and collection

The study questionnaire was developed by the Mayo Clinic Survey Centre and data acquired via this instrument among other autoimmune liver disease cohorts have been published previously. The survey contains questions regarding demographics, anthropometric features, education, lifestyle and environmental exposures as well as extensive personal and familial medical history. In total, the survey includes 70 primary and 300 secondary questions covering 37 pages with responses provided using scantron technology (Table S1). This study instrument was either given directly to or mailed to enrolled participants along with a prepaid return envelope. In the case of study participants (cases and controls) who did not return the first questionnaire, a second questionnaire was mailed within 2 months from the initial contact. At the time of study completion, the GRACE study included 512 AIH patients and 358 (70% response rate) had returned the study questionnaire. The control group included 563 participants (87% response rate).

Statistical analysis

Information collected by the questionnaires was double entered into a SAS database. Each question was summarized by descriptive statistics for both AIH cases and controls. The P-values were calculated using logistic regression models, adjusting for age, gender and education. Statistical analysis was conducted in R version 3.6.2 (R Foundation for Statistical Computing) and a P-value of .05 was considered significant.

RESULTS

Demographics

Demographic comparison of AIH cases and controls is shown in Table 1. Cases were more likely to be female (79.3%, P = .045), younger at study completion (median = 55 yrs (years) old, (43 quartile 1(Q1), 64 (quartile 3(Q3)), P < .001)), less likely Caucasian (96.2%, P < .001) and have more college (60.3%) but less professional educational training beyond college (19.1%, P < .001) than healthy controls. Race remained statistically different between cases and controls after adjustment for age of recruitment, gender and level of education.

Medical history: autoimmune and other conditions

AIH cases were more likely to have any another autoimmune disease in addition to AIH compared to controls (22.3% vs 10.1%, P < .001) (Table 2). The most common autoimmune disease found in cases in addition to AIH was autoimmune thyroid disease (17.4%), followed...
3.3 | Gynaecologic and reproductive history

Reproductive history was completed by 284 AIH cases and 414 controls (Table 3). Age at study completion was lower in cases compared to controls (55 yrs (44, 63) vs 61.2 yrs (54.3, 67.4)). There was no difference in the age of first menarche between the study groups, nor when age when menstruation stopped. AIH cases were similar to cases in regards to ever being pregnant and total live births, but had less lifetime pregnancies (1 (1, 2) vs 3 (3, 4), P < .001) compared to controls (Table 3).

AIH cases were more likely to have ever used oral contraceptives (OC) (83% vs 73.7%, P = .006) compared to controls, but the duration of OC use between groups was similar (Table 3). Among those that used OC, the age of OC start was significantly younger in AIH cases compared to controls (19 yrs (18, 22) vs 21 yrs (21, 25), P = .0001). Among cases with a history of OC use, 93.4% were exposed to OC prior to AIH diagnosis. Ever use of hormone replacement therapy (HRT) was lower in cases compared to controls (28.5% vs 60.1%, P < .001). Among those that used HRT, AIH cases tended to be younger at HRT start compared to controls (45.5 yrs (37.2, 50) vs 60.1% vs 49 yrs (44, 52), P = .001). Among cases with a history of HRT use, and 91.1% were exposed to HRT prior to AIH diagnosis.

3.4 | Health and lifestyle exposures

AIH cases were not any more likely to have every regularly smoked cigarette as controls (38.4% vs 41.2%, P = .888) (Table 4). Among those that had smoked, the age started smoking and years smoked regularly were no different between cases and controls. AIH cases were less likely to have been exposed to second-hand smoke at work (35.2% vs 51.6%, P < .001) but not at home (62.1% vs 69.2%, P = .748). However, AIH cases were more likely than controls to be current regular smokers (18.9% vs 7.4%, P = .022). AIH cases were less likely than controls to be current drinkers (27.7% vs 76.7%, P < .001). Among individuals that ever consumed alcohol, AIH cases

### TABLE 2 Autoimmune disease and other medical history in autoimmune hepatitis cases and controls

| Autoimmune Diseases                     | Mayo Controls (N = 563) | AIH Cases (N = 358) | P-value* |
|-----------------------------------------|-------------------------|---------------------|----------|
| Celiac disease                          | 4 (0.7%)                | 14 (4.1%)           | .017     |
| Raynaud's syndrome                      | 24 (4.3%)               | 19 (5.6%)           | .31      |
| RA                                      | 29 (5.2%)               | 40 (11.8%)          | <.001    |
| Sjogren's syndrome                      | 6 (1.1%)                | 19 (5.6%)           | <.001    |
| T1DM                                    | 2 (0.4%)                | 4 (1.2%)            | .86      |
| Thyroid disease                         | 100 (17.8%)             | 59 (17.4%)          | .86      |

| Other Medical Conditions                |                         |                     |          |
|-----------------------------------------|-------------------------|---------------------|----------|
| GERD                                    | 157 (27.9%)             | 137 (40.4%)         | <.001    |
| Gall stones                             | 88 (15.6%)              | 70 (20.9%)          | .014     |
| Myocardial infarction                   | 15 (2.7%)               | 5 (1.5%)            | .80      |
| Shingles                                | 71 (12.6%)              | 52 (15.4%)          | .040     |
| UTI                                     | 191 (33.9%)             | 181 (53.6%)         | <.001    |
| Recurrent UTI                           | 89 (15.9%)              | 81 (23.5%)          | .006     |

| Number of recurrent UTIs               |                         |                     |          |
|-----------------------------------------|-------------------------|---------------------|----------|
| Once every 2 years                      | 33 (38.8%)              | 21 (25.9%)          |          |
| Once every year                         | 18 (21.2%)              | 24 (29.6%)          |          |
| Two or more times a year                | 34 (40.0%)              | 36 (44.4%)          |          |

Abbreviations: AIH, autoimmune hepatitis; RA, rheumatoid arthritis; T1DM, Type 1 diabetes mellitus; UTI, urinary tract infection.

*P-values are adjusted for age at time of recruitment, gender and education based on logistic regression analysis.
TABLE 3  Gynaecologic and reproductive history of female autoimmune hepatitis cases and controls

|                          | Mayo Controls (N = 414) | AIH Cases (N = 284) | P-value* |
|--------------------------|-------------------------|---------------------|----------|
| Age at recruitment, yrs* | 61.2 (54.3, 67.4)       | 55 (44, 63)         | —        |
| Education                |                         |                     |          |
| Some high school         | 81 (19.8%)              | 55 (19.9%)          | —        |
| College                  | 217 (52.9%)             | 173 (62.5%)         |          |
| Professional training    | 112 (27.3%)             | 49 (17.7%)          |          |
| beyond college           |                         |                     |          |
| Age first menarche       |                         |                     |          |
| Less than 12 yrs         | 65 (18.2%)              | 46 (17.4%)          | .18      |
| 12 yrs                   | 97 (27.2%)              | 65 (24.5%)          |          |
| 13 yrs                   | 98 (27.5%)              | 69 (26.0%)          |          |
| 14 yrs                   | 53 (14.8%)              | 42 (15.8%)          |          |
| 15 yrs or older          | 44 (12.3%)              | 43 (16.2%)          |          |
| Age menstruation ceased, yrs* | N = 306, 49 (43, 52)  | N = 161, 46 (41, 50) | .08      |
| Ever pregnant            | 356 (86.4%)             | 220 (79.1%)         | .34      |
| Number of pregnancies*   | 3 (2, 4)                | 1 (1.2)             | <.001    |
| Number of live births*   | 2 (2, 3)                | 1 (1.2)             | .07      |
| Age first pregnancy      |                         |                     |          |
| 17 yrs or younger        | 27 (7.6%)               | 21 (9.7%)           | .08      |
| 18 yrs                   | 21 (5.9%)               | 8 (3.7%)            |          |
| 19 yrs                   | 27 (7.6%)               | 18 (8.3%)           |          |
| 20 to 24 yrs             | 161 (45.2%)             | 74 (34.1%)          |          |
| 25 to 29 yrs             | 85 (23.9%)              | 54 (24.9%)          |          |
| 30 to 34 yrs             | 27 (7.6%)               | 30 (13.8%)          |          |
| 35 to 39 yrs             | 8 (2.2%)                | 12 (5.5%)           |          |
| 40 yrs or older          | 0 (0.0%)                | 0 (0.0%)            |          |
| Pruritus during pregnancy| 301 (94.1%)             | 163 (88.1%)         | .29      |
| Ever OC                  | 302 (73.7%)             | 230 (83.0%)         | .006     |
| Age OC start, yrs*       | 21 (19, 25)             | 19 (18, 22)         | <.001    |
| Years taking OC          |                         |                     |          |
| Less than 1 yrs          | 29 (9.8%)               | 23 (10.0%)          | .73      |
| 1 to 5 yrs               | 118 (39.9%)             | 80 (34.9%)          |          |
| 6 to 10 yrs              | 71 (24%)                | 64 (27.9%)          |          |
| 11 yrs or more           | 78 (26.4%)              | 62 (27.1%)          |          |
| Hormone replacement      | 247 (60.1%)             | 79 (28.5%)          | <.001    |
| therapy (HRT) ever       |                         |                     |          |
| Age HRT Start, yrs*      | 49 (44, 52)             | 45.5 (37.2, 50)     | .001     |

Abbreviations: AIH, autoimmune hepatitis; HRT, hormone replacement therapy; OC, oral contraceptives; yrs, years.
*variables summarized as median (Q1, Q3).
*P-values are adjusted for age at time of recruitment and education based on logistic regression analysis.

TABLE 4  Smoking and alcohol history of AIH cases and controls

|                          | Mayo Controls (N = 563) | AIH Cases (N = 358) | P-value* |
|--------------------------|-------------------------|---------------------|----------|
| Tobacco exposure         |                         |                     |          |
| Every regularly smoked   | 231 (41.2%)             | 134 (38.4%)         | .89      |
| Age started smoking, yrs*| 18 (16, 20)             | 18 (16, 20)         | .80      |
| Currently smoke regularly| 17 (7.4%)               | 24 (18.9%)          | .022     |
| Smoked regularly, yrs*   | 17 (9, 29)              | 19.5 (8, 32)        | .13      |
| Ever lived with smoker   | 389 (69.2%)             | 216 (62.1%)         | .75      |
| Ever worked with smoker  | 288 (51.6%)             | 122 (35.2%)         | .001     |
| Ever lived or worked with smoker | 449 (79.9%) | 246 (70.7%) | .17    |
| Pack yrs prior AIH diagnosis | NA                  | 17.2 (9.6, 26.4) |          |
| Alcohol exposure         |                         |                     |          |
| Currently drink alcohol  | 76.30%                  | 27.70%              | <.001    |
| Average alcoholic drinks per month | | | | |
| 1 to 10 drinks per month | 200 (46.8%)             | 34 (50.0%)          | .32      |
| 11 to 20 drinks per month| 76 (17.8%)              | 16 (23.5%)          |          |
| 21 to 30 drinks per month| 75 (17.6%)              | 9 (13.2%)           |          |
| 31 to 40 drinks per month| 39 (9.1%)               | 3 (4.4%)            |          |
| 41 to 50 drinks per month| 15 (3.5%)               | 6 (8.8%)            |          |
| 51 or more drinks per month| 22 (5.2%)             | 0 (0.0%)            |          |
| Yrs drank alcohol*       | 40 (31, 47)             | 27 (12, 37)         | <.001    |

Abbreviation: Yrs, years.
*variables summarized as median (Q1, Q3).
*P-values are adjusted for age at time of recruitment and education based on logistic regression analysis.

had less duration of consumption (27 years (12, 37) vs 40 (31, 47), P < .001) compared to controls.

3.5 | Childhood diseases and immunizations

AIH cases were less likely to have the infectious childhood disease mumps (32.4% vs 53.1%, P = .011) and rheumatic fever (1.1% vs 4.4%,
cases more frequently had vaccination to chicken pox (38% vs 28.1%, \(P = .005\)), measles (66.5% vs 39.3%, \(P < .001\)), mumps (58.7% vs 34.6%, \(P < .001\)), rubella (55.3% vs 32.7%, \(P < .001\)), pertussis (59.8% vs 40.1%, \(P < .001\)) and pneumococcus (47.2% vs 39.4%, \(P = .002\)) (Table 5).

3.6 | Family history

Detailed history of autoimmune diseases, gastrointestinal and liver conditions among both first-degree and second-degree relatives (FDRs and SDRs) was collected in cases and in controls (Table S2). The AIH case pedigrees included 2,126 FDRs and 4,068 SDRs. Controls had 3,753 FDRs and 5,210 SDRs pedigrees available. AIH cases of FDRs were more likely to have celiac disease (3.6%, \(P = .001\)), lupus (3.9%, \(P = .028\)), multiple sclerosis (3.9%, \(P < .001\)), RA (13.4%, \(P < .001\)), Sjogren's syndrome (2.8%, \(P < .001\)), T1DM (10.6%, \(P < .001\)) and colon cancer (10.3%, \(P < .001\)) compared to control FDRs. AIH cases of SDRs were more likely to have RA (6.7%, \(P < .001\)) and T1DM (5%, \(P < .001\)) compared to control SDRs.

3.7 | Environmental risk discrepancy according to gender

Prior disparities among genders in AIH studies have revealed that male patients have higher frequencies of DRB1*03:01, worse overall survival and increased development of hepatocellular cancer.\(^{13-15}\) Thus, stratification of reported medical histories and exposures were completed according to gender. Observed differences between medical histories in cases and controls were most often associated with female gender (Table S3).

4 | DISCUSSION

In this study, patients with AIH compared to controls were more likely to report history of UTI, recurrent UTIs, gallstones, multiple vaccinations (chicken pox, measles, mumps, rubella, pertussis and pneumococcal), younger age of OC start, ever OC use and current smoking. Moreover, AIH cases were less likely to report a history of working with a smoker, mumps, rheumatic fever, pregnancies and HRT. Finally, patients with AIH often reported concurrent autoimmune diseases (including celiac disease, RA, and Sjogren’s syndrome) as well as FDR with autoimmune diseases (celiac disease, MS, RA, SS, T1DM) as well as SDR (RA, T1DM).

The GRACE study is the largest cohort of AIH cases to date that has systematically evaluated environmental risk factors associated with the development of disease, but observations in this study should still be interpreted in the context of the study design. Significant differences between case and control responses in this study do not necessarily indicate disease causation, but must be interpreted in the hypothetical web of interactions (environment and genetics) that underscore disease development. Despite a systematic approach in this study, we also realize that there are many unmeasured environmental exposures starting at conception. However, we utilized a questionnaire that has been implemented in other autoimmune liver disease cohorts and collected environmental exposures that have either biologic plausibility in autoimmunity or have been associated with other chronic diseases. To our knowledge, only one other study\(^{16}\) has assessed a diverse array of environmental risk factors in AIH. Ngu \textit{et al} reported the only factor that independently increased AIH risk was exposure to antibiotics within 12 months of diagnosis among 72 AIH cases.\(^{16}\) This study also observed that alcohol and having a childhood home with wood heating was associated with reduced risk of AIH development. Unfortunately, our survey instrument did not assess drug exposure history, but we suspect this finding from the Ngu \textit{et al} study could represent an enrichment of drug-induced AIH. Mechanistically, this likely represents a subtype of AIH as immunosuppression removal can be completed in a high proportion of patients\(^{8}\) and has been shown to have differing genetic risks than idiopathic AIH.\(^{17}\) Our findings of alcohol use in our cohort were supportive of a prior observation,\(^{18}\) as we observed AIH cases were less likely to be current drinkers and had less alcohol duration on average than controls. Alcohol has been shown to be protective against progression of other autoimmune diseases (le SLE\(^{19}\) and RA\(^{20}\)) and may be secondary to impaired presentation of foreign antigen by antigen-presenting cells.\(^{21}\) Despite a possible role of protection in AIH, alcohol use beyond diagnosis may be

TABLE 5 | Childhood disease and immunization history in AIH Cases and Controls

|                        | Mayo Controls (N = 563) | AIH Cases (N = 358) | \(P\) value * |
|------------------------|-------------------------|---------------------|---------------|
| **Childhood diseases**  |                         |                     |               |
| Chicken Pox            | 399 (70.9%)             | 258 (72.1%)         | .09           |
| Measles                | 320 (56.8%)             | 134 (37.4%)         | .12           |
| Mumps                  | 299 (53.1%)             | 116 (32.4%)         | .011          |
| Rheumatic Fever        | 25 (4.4%)               | 4 (1.1%)            | .028          |
| **Vaccination history**|                         |                     |               |
| Chicken Pox            | 158 (28.1%)             | 136 (38.0%)         | .005          |
| Influenza              | 426 (75.7%)             | 276 (77.1%)         | .23           |
| Measles                | 221 (39.3%)             | 238 (66.5%)         | <.001         |
| Mumps                  | 195 (34.6%)             | 210 (58.7%)         | <.001         |
| Rubella                | 184 (32.7%)             | 198 (55.3%)         | <.001         |
| Small Pox              | 326 (57.9%)             | 209 (58.4%)         | .11           |
| Pertussis              | 226 (40.1%)             | 214 (59.8%)         | <.001         |
| Pneumococcal           | 222 (39.4%)             | 169 (47.2%)         | .002          |
| Polio                  | 452 (80.3%)             | 292 (73.2%)         | .38           |

*\(P\)-values are adjusted for age at time of recruitment and education based on logistic regression analysis.
very different. Mortality hazard ratio has been shown higher in alcoholic AIH patients versus those without alcohol history, thus clinical screening for alcohol use and expressed alcohol avoidance remain important.28

Smoking has not been assessed previously in AIH patients, yet it has been well documented in other autoimmune liver diseases PSC and PBC. In PSC, smoking most recently has been shown to only associate with disease among patients that also had concurrent IBD.29 On the other hand, PBC has routinely been associated with smoking.6,22-24 In our study, we observed no difference in AIH cases compared to controls among frequency of “ever regularly smoked”, age of smoking start and years of regularly smoked. However, we did observe that AIH cases were more likely to currently smoke (18.9% vs 7.4%, adjusted P-value = 0.022) but less likely to ever work with a smoker (35.2% vs 51.6%, adjusted P-value <.001). These conflicting results may have multiple explanations that could include a dose effect of smoking, variable known/unknown genetic predispositions in our cohort or highlight the tenuous balance between pro- and anti-inflammatory attributes of smoking among populations. Even despite the relative consistency of smoking associated with PBC in prior studies, published cohorts have shown conflicting assessments.25,26 Cigarette smoking has a diverse immunomodulatory effect and includes increases in proinflammatory cytokines and tumour necrosis factor alpha27 as well as decreased activation of antigen-presenting cells with diminished Th1 and Th17 polarizing (reduced IL-12 and IL-23) effect in the setting of lipopolysaccharide.28 AIH patients that smoked prior to diagnosis reported a median of 17.2 pack-years, whereas in a prior PBC study,6 PBC cases had a median of 10.5 pack-years. Beyond clarity of impact on risk of disease development, AIH further lacks investigation into impact of smoking on disease and fibrosis progression and remains an important research question. This remains particularly important, as nearly 20% of our AIH cohort was smoking at time of survey completion.

Notably, a novel and possibly most important finding in this study was the observation of increased UTI diagnosis (53.6% vs 33.9%) and recurrent UTIs (23.5% vs 15.9%) among AIH cases versus controls (Table 2). This observation in PBC was first made in 198439 and has been observed prior to diagnosis, thus less likely a result of predisposing risk from autoimmune disease. Similarly, PSC cases have reported higher frequencies of recurrent UTI compared to controls in a prior study with mechanistic uncertainty,5 but may be a result of molecular mimicry of bacterial antigens and host proteins.30 Certainly PBC and PSC are very different diseases than AIH, as both are resultant of dysregulated inflammatory response associated with small to large bile ducts as opposed to interface and lobular inflammation. Reconciliation of observed increased “ever UTI” and recurrent UTI in AIH cases compared to controls is capable when considering PBC, as both diseases have female predominance with similar age medians of onset. Yet, not true for PSC, as often a male dominant disease of young onset. Risk factor stratification according to gender supports the gender-specific risk observation, as the risk of UTI and recurrent UTI was only associated with female cases in this study (Table S2). Increased “ever UTI” and recurrent UTIs in AIH may be a surrogate for other underlying aetiology such as antibiotic use, fitting with the Ling et al study.38 Furthermore, drug-induced AIH is well described, and likely represents a subtype of rather heterogeneous AIH populations. Finally, one should consider that both PBC31 and AIH4 have shown increased frequency of other historical infections (Epstein-Barr virus, CMV), and may suggest a role for multiple infections (with risk for molecular mimicry) in autoimmune liver disease development.32,33

Given female predominance of AIH, we must carefully consider the results of documented exposures that correlate with gender. Our data revealed that AIH cases were more likely to ever use OC, start OC younger (but similar duration), have fewer lifetime pregnancies and less likely to have ever used HRT compared to controls. The observed difference in AIH protection (HRT) and risk (OC use) observed between these oestrogen containing pharmaceuticals may relate to the inherent timing of administration. Infrequent HRT use may be driven by behaviours of cautious providers aware of patients known liver disease (average age AIH diagnosed 50 years old (37, 58)), Similar observations (less HRT use) have been observed in females with PSC,5 yet in PBC, HRT and OC use have been associated with disease protection.34 Generally speaking, oestrogens are associated with known anti-inflammatory properties via multiple mechanisms.35 Sex hormones are also important in the complex development of both the innate and adaptive immune system34 and have been associated with protection among other autoimmune diseases such as RA and MS.37 Further examination of hormone-related effects on AIH development and disease progression may illuminate key pathogenetic differences among autoimmune liver diseases.

Historically, only in few, historical and rare cases, has autoimmune pathology been firmly linked with particular vaccines. An observed polyarthritis associated with the 1976-1977 vaccination campaign against swine influenza is one such example.38 We report increased prevalence of chicken pox, measles, mumps, rubella, pertussis and pneumococcal vaccination among AIH cases compared to controls. We also observed less infectious reports of mumps and rheumatic fever in AIH cases. Vaccines are inherently immunogenic, shaping a host immunologic response to a focused antigen that remains controlled. Prior reports of vaccination association with AIH have been mostly case based,39,40 without strong evidence linking current vaccine protocols to increased disease development. However, we believe further investigation of vaccines as a prospective focus may help to elucidate a clear association with autoimmune liver disease. Furthermore, vaccine-related AIH risk was associated with female gender, except for pertussis vaccine. These observed risks may highlight fundamental disease differences in pathogenesis between males and females including other gender-specific risks and interactions (increased HLA-DRB1*03:01 in males13,14 and hormonal therapy or pregnancy in females).

We admit that given the observational approach to our study, there are limitations worth considering. Despite being one of the first systematic approaches to examine environmental risk in well-phenotyped AIH case development, the size of our study remains moderate. We were dependent on patient-reported data for many
outcomes of interest which may introduce recall bias. Furthermore, this case-control study does not include a disease control group for direct comparison, yet two other liver disease populations (PBC and PSC) have utilized this questionnaire previously.\(^5\),\(^6\) We were careful to compare our findings to these prior studies, yet given the inherent disease differences, we must consider our observations in the context of AIH. This methodology is necessary until well-cultivated prospective studies of AIH are established and completed. We believe our cohort is an excellent representation of AIH patients and well poised to address these questions, as other key findings support prior observations of similar demographics, concurrent autoimmune disease and enrichment of FDR (and few SDR) with autoimmune diseases (Table S2).

In summary, we report novel associations between a variety of exogenous risk factors and AIH using an established AIH cohort (GRACE study) and healthy controls. History of UTI, recurrent UTI, ever and earlier start of OC, current smoking and a variety of immunizations were associated with the development of AIH. On the other hand, history of mumps, HRT use, history of working with a smoker were protective against AIH. Despite plausible biologic mechanisms, these associations do not indicate disease causation. Yet, counselling on smoking cessation, screening for other autoimmune illnesses at diagnosis and during follow-up and careful antibiotic stewardship remain important and are currently actionable by clinicians. We advocate for multicentre prospective studies of AIH to better understand modifiable risk factors in the setting of a permissive genetic framework.

ETHICS APPROVAL STATEMENT

This study included cohorts that adhere to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the Institutional Review Board of Indiana University and Mayo Clinic.

CONFLICT OF INTEREST

All included authors declare no outside interests that are directly or significantly related to this paper.

AUTHOR CONTRIBUTIONS

Craig Lammert: assembly/interpretation of data, drafting and revision of manuscript. Sai Chalasani: assembly of data, review of manuscript. Bryan McCauley: statistical analysis, critical revision of statistics and results. Elizabeth J. Atkinson: statistical analysis, critical revision of statistics and results. Konstantinos N. Lazaridis: Conception of study and design, collection and assembly of data, drafting and approval of final manuscript version.

PATIENT CONSENT STATEMENT

All participants in the study had informed consent collected by study staff.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1. Lammert C, McKinnon EJ, Chalasani N, et al. Novel HLA class I alleles outside the extended DR3 haplotype are protective against autoimmune hepatitis. *Clin Transl Gastroenterol*. 2019;10:e00032.
2. de Boer YS, van Gerven NMF, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. *Gastroenterology*. 2014;147:443-52.e5.
3. Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. *Expert Rev Gastroenterol Hepatol*. 2013;7:365-385.
4. Christen U, Hintermann E. Pathogens and autoimmune hepatitis. *Clin Exp Immunol*. 2019;195:35-51.
5. Eaton JE, Juran BD, Atkinson EJ, et al. A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. *Aliment Pharmacol Ther*. 2015;41:980-990.
6. Lammert C, Nguyen DL, Juran BD, et al. Questionnaire based assessment of risk factors for primary biliary cirrhosis. *Dig Liver Dis*. 2013;45:589-594.
7. Lammert C, Juran BD, Schlicht E, et al. Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. *Clin Gastroenterol Hepatol*. 2014;12:1562-1568.
8. Björnsson ES, Bergmann O, Jonasson JG, et al. Drug-induced autoimmune hepatitis: Response to corticosteroids and lack of relapse after cessation of steroids. *Clin Gastroenterol Hepatol*. 2017;15:1635-1636.
9. Cai W, Ran Y, Li Y, et al. Intestinal microbiome and permeability in patients with autoimmune hepatitis. *Best Pract Res Clin Gastroenterol*. 2017;31:669-673.
10. Srivastava S, Boyer JL. Psychological stress is associated with relapse in type 1 autoimmune hepatitis. *Liver Int*. 2010;30:1439-1447.
11. Lammert C, Comerford M, Love J, et al. Investigation gone viral: application of the social mediashere in research. *Gastroenterology*. 2015;149:839-843.
12. EASL Clinical Practice Guidelines. Autoimmune hepatitis. *J Hepatol*. 2015;63:971-1004.
13. Kirstein MM, Metzler F, Geiger E, et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. *Hepatology*. 2015;62:1524-1535.
14. Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. *J Hepatol*. 2014;60:612-617.
15. Dakhoul L, Jones KR, Gawrieh S, et al. Older age and disease duration are highly associated with hepatocellular carcinoma in patients with autoimmune hepatitis. *Dig Dis Sci*. 2019;64:1705-1710.
16. Ngu JH, Geary RB, Frampton CM, et al. Autoimmune hepatitis: the role of environmental risk factors: a population-based study. *Hepatol Int*. 2013;7:869-875.
17. de Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. *Clin Gastroenterol Hepatol*. 2017;15:103-112.e2.
18. Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. *J Hepatol*. 2014;60:612-617.
19. Schubert C, Fuchs D. The relationship between alcohol intake and cellular immune activity in systemic lupus erythematosus may

ORCID

Craig Lammert https://orcid.org/0000-0003-3809-640X
Konstantinos N. Lazaridis https://orcid.org/0000-0002-0437-681X
change from inhibitory to stimulatory within 2 months of study: findings from an integrative single-case study. Clin Rheumatol. 2010;29:229-230.
20. Lu B, Solomon DH, Costenbader KH, et al. Alcohol consumption and risk of incident rheumatoid arthritis in women: a prospective study. Arthritis Rheumatol. 2014;66:1998-2005.
21. Aloman C, Gehring S, Winterneyer P, et al. Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology. 2007;132:698-708.
22. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis. 2014;34:265-272.
23. Corpechot C, Gaouar F, Chrétien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol. 2012;56:218-224.
24. Gatselis NK, Zachou K, Lygoura V, et al. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. Eur J Intern Med. 2017;42:81-88.
25. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181-1188.
26. Mantaka A, Koulentaki M, Chlouverakis G, et al. Primary biliary cirrhosis in a genetically homogeneous population: disease associations and familial occurrence rates. BMC Gastroenterol. 2012;12:110.
27. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34:J258-J265.
28. Kroening PR, Barnes TW, Pease L, et al. Cigarette smoke-induced oxidative stress suppresses generation of dendritic cell IL-12 and IL-23 through ERK-dependent pathways. J Immunol. 2008;181:1536-1547.
29. Burroughs AK, Rosenstein IJ, Epstein O, et al. Bacteriuria and primary biliary cirrhosis. Gut. 1984;25:133-137.
30. Wang JJ, Yang GX, Zhang WC, et al. Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice. Clin Exp Immunol. 2014;175:192-201.
31. Shapira Y, Agmon-Levin N, Renaudineau Y, et al. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden. Exp Mol Pathol. 2012;93:386-390.
32. Taubert R, Diestelhorst J, Junge N, et al. Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. Sci Rep. 2018;8:17452.
33. Pischke S, Gisa A, Suneetha PV, et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One. 2014;9:e85330.
34. Corpechot C, Chrétien Y, Chazouillères O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53:162-169.
35. Nilsson BO. Modulation of the inflammatory response by estrogens with focus on the endothelium and its interactions with leukocytes. Inflamm Res. 2007;56:269-273.
36. Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279.
37. Khan D, Ansar AS. The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol. 2015;6:635.
38. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110:105-123.
39. Veerappan GR, Mulhall BP, Holtzmuller KC. Vaccination-induced autoimmune hepatitis. Dig Dis Sci. 2005;50:212-213.
40. Sasaki T, Suzuki Y, Ishida K, et al. Autoimmune hepatitis following influenza virus vaccination: two case reports. Medicine (Baltimore). 2018;97:e11621.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Lammert C, Chalasani SN, Atkinson EJ, McCauley BM, Lazaridis KN. Environmental risk factors are associated with autoimmune hepatitis. Liver Int. 2021;00:1–8. https://doi.org/10.1111/liv.14944